Compare Globus Medical Inc. Class A Common Stock (GMED) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Goldman Sachs Group Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Goldman Sachs Group Inc trades at $882.23 (market cap $259.70B). The key difference: Goldman Sachs Group Inc is far larger — about 25.3× Globus Medical Inc. Class A Common Stock's market cap, and Goldman Sachs Group Inc pays a 2.24% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Goldman Sachs Group Inc for 100 Days on average.
| GMED | GS | |
|---|---|---|
Market Cap | $10.25B | $259.70B |
Volume | 1,108,124 | 4,939,526 |
Sector | Health | Financials |
52-Week High | $96.82 | $1.15K |
52-Week Low | $58.33 | $744.60 |
Typical Hold Time | 0 Days | 100 Days |
Enterprise Value | $9.76B | $263.03B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Goldman Sachs (GS) trades at $891.91, down 0.23% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q3 2026) and improving profitability (net margin 31.68%, ROE 18.33%). Revenue growth accelerated to $58.28B in 2025 with guidance targeting $70B. Recent news highlights AI expansion and wealth management growth, though Q3 FICC business may soften.
GS presents a compelling value opportunity with attractive valuation (P/E 13.77) and 40% analyst buy ratings. Upside to $1,160 consensus target offers ~30% potential, supported by dividend growth and operational efficiency. Risks include market volatility, competitive pressures, and execution on AI/wealth management expansion. The balance sheet remains robust with $122B equity despite negative operating cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
